Exact Sciences (EXAS) Gains as NCQA Updates Colorectal Cancer Screening Measure
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Exact Sciences (NASDAQ: EXAS) gains as NCQA updates colorectal cancer screening measure.
The National Committee for Quality Assurance (NCQA) has updated the HEDIS®Colorectal Cancer Screening measure in order to respond to recently revised scientific guidelines by the US Preventive Services Task Force.
The USPSTF recommends colorectal cancer screening that includes a variety of tests, and noted that offering more options and sharing decision making with patients may be an opportunity to improve screening rates.
According to the USPSTF Recommendation Statement, Screening for Colorectal Cancer, 2016: “…offering choice in colorectal cancer screening strategies may increase screening uptake. As such, the screening tests are not presented in any preferred or ranked order; rather, the goal is to maximize the total number of persons who are screened because that will have the largest effect on reducing colorectal cancer deaths.” Colorectal Cancer Screening is a long-standing, widely used measure.
Changes to the measure align with USPSTF recommendations, and will be published in the October Technical Specifications Update. The updated measure is effective for HEDIS 2017.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Western Union (WU) Admits Anti-Money Laundering and Consumer Fraud Violations, Forfeits $586M in Settlement
- Exclusive: Lingerie maker Victoria's Secret looks to uncover supply chain issues
- U.S. closing Tesla (TSLA) autopilot death investigation without demanding recall - Reuters
Create E-mail Alert Related CategoriesCorporate News, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!